Case Report

Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy

Anna Robuccio\(^{a,b,1}\), Paddy Ssentongo\(^{a,b,1}\), Michael D. Sather\(^{d}\), David F. Claxton\(^{e}\), Frank G. Gilliam\(^{a,c,d,*}\)

\(^{a}\) Center for Neural Engineering, Science and Mechanics, The Pennsylvania State University, University Park, PA 16802, USA
\(^{b}\) Department of Engineering, Science and Mechanics, The Pennsylvania State University, University Park, PA 16802, USA
\(^{c}\) Department of Neurology, Penn State Hershey College of Medicine, 500 University Drive, Hershey, PA 17033, USA
\(^{d}\) Department of Neurosurgery, Penn State Hershey College of Medicine, 500 University Drive, Hershey, PA 17033, USA
\(^{e}\) Penn State Cancer Institute, Penn State Hershey College of Medicine, 500 University Drive, Hershey, PA 17033, USA

1. Introduction

The definition of “epileptic myoclonus” has changed several times over the past 3 decades. Myoclonus is currently defined as sudden involuntary jerking of a muscle or groups [2]. Myoclonus is associated with multiple epilepsy syndromes such as juvenile myoclonic epilepsy and the progressive myoclonic epilepsies. Although the neurophysiology of myoclonus is incompletely understood [1], spatial and temporal amplification within relevant networks may cause the epileptic motor activity [3].

Recently, graft versus host disease was observed to cause central nervous system (CNS) complications following allogenic stem cell transplants (allo-HSCTs) [4–9]. However, very few patients have presented with myoclonus [6,9]. We describe an allo-HSCT patient who developed chronic GVHD, associated with intractable myoclonic seizures. This appears to be an uncommon example of symptomatic myoclonic epilepsy, defined as clinical myoclonus associated with diffuse polyspike activity on EEG following a known cerebral insult.

2. Case

A 48-year-old male was diagnosed with Philadelphia chromosome positive acute myelogenous leukemia in 9/03/2008. He received a 7 + 3 induction chemotherapy (3 days of daunorubicin and 7 days of continuous infusion of cytosine arabinoside) in September with 400 mg of imatinib given for 14 days of the induction. A bone marrow on 10/23/2008 was consistent with a complete remission — there was no morphological evidence of residual acute leukemia. At that time, quantitative PCR for bcr-abl p210, previously positive, was negative. Imatinib was resumed at 800 mg daily. The patient subsequently remained in complete morphological and molecular remission of his leukemia. He then received nonmyeloablative conditioning chemotherapy with fludarabine and cyclophosphamide prior to allogenic stem cell transplantation with matched unrelated donor stem cells on 2/23/09 without incident. He remained stable and tolerated the course well.

The patient recovered normal hematopoiesis rapidly, but donor engraftment as documented by XY fluorescence in-situ hybridization (FISH) was initially modest — XX was initially only 1.4%.

Between 06/22/2009 and 07/23/2009, his XX engraftment rose from 9.2% to 98.0%. He was diagnosed with chronic graft versus host disease on 10/20/2011 (more than two years after stem cell transplant); the patient presented with significant irritation and thickening of the
mucosae over the tongue and buccal surfaces. He was treated with topical oral dexamethasone swish and spit and tacrolimus.

In June 2012, the patient presented with myoclonic jerks involving his arms and legs. They caused occasional falls, but he denied any loss of consciousness. In spite of levetiracetam, he continued to have episodes multiple times per day. He was admitted to the neurology service after a myoclonic jerk that resulted in a fall with loss of consciousness. His neurological exam was unremarkable except for frequent myoclonic jerks of the extremities with brief alteration in awareness and responsiveness. Brain magnetic resonance imaging revealed periventricular white matter lesions (Fig. 1). Electroencephalography showed frequent generalized 40–70 µV polyspike activity that occurred in runs lasting from 0.5–3 s, maximal in the frontocentral regions (Fig. 2). This activity was seen spontaneously and during photic stimulation. Perampanel improved his symptoms by 40%. However, his seizures then worsened and were intractable to levetiracetam, valproic acid, topiramate, lorazepam, clonazepam, zonisamide, and lacosamide. Vagal nerve stimulation did not improve the frequency or severity of the myoclonic jerks. For chronic oral graft versus host disease, the patient requires ongoing immunosuppression with tacrolimus, mycophenolate, and oral topical dexamethasone. Attempts to taper tacrolimus have resulted in problematic ulcerative oral inflammation. In spite of immunosuppressive agents, he experiences some ongoing oral mucosal irritation.

3. Discussion

Chronic GVHD is recognized to cause neurological manifestations [4–9], but little is known about its relationship with symptomatic myoclonus, resulting in a scarcity of information of the natural history or treatment outcomes. Initially, our patient received partial relief from perampanel, but his condition proved to be intractable to more than eight antiepileptic drugs and vagal nerve stimulation. He continues to have 3 or more seizures per hour, resulting in up to 100 per day. We summarize several case studies written within the last 30 years in Table 1. However, nearly all reported patients have died or are still suffering from severe epilepsy. Further research is needed to determine an appropriate protocol for patients who develop myoclonus following GVHD.

Conflict of interest statement

The authors declare that there are no conflicts of interest.
| Author          | Type of transplant/GVHD | Number of patients | Clinical features                                      | MRI/neuropathology                                      | CSF | EEG | Other                                         | Type of seizures | Treatment for epilepsy | Treatment outcome | Time of onset after transplant |
|-----------------|-------------------------|--------------------|-------------------------------------------------------|--------------------------------------------------------|-----|-----|---------------------------------------------|------------------|------------------------|----------------------|-------------------|
| Starzl et al.   | OLT                     | 9                  | Leg spasticity, decreased mentation, right hemiparesis, akinetic mutism, stupor and coma, seizures | Multifocal areas of infarction in cerebral cortex and basal ganglia, CPM | N/A |     | Diffusely slow and nonfocal              | Cerebral angiography: thrombotic or embolic disease | G, F                 | N/A                  | Died                | Between 3 and 72 days |
| Adams et al.    | OLT                     | 13                 | Encephalopathy, spasticity, seizures                  | N/A                                                   | N/A |     | Focal EEG abnormalities, right posterior quadrant abnormalities, right sided continuous spikes | CAT scan showing low density areas right occipital lobe | G (10), F (1), M (2) | Phenytoin (worked in 10 of 13) | Died in SE (2)    | Median: 7 days       |
| Iwasaki et al.  | allo-HSCT               | 2                  | Encephalopathy, spasticity, seizures                  | Cortical atrophy, ventricular dilatation              | EP, Pleo |     | Autopsy: diffuse infiltration of white matter with CD3 lymphocytes | Biopsy of colonic mucosa: persistent GVHD | G                | N/A                  | Died                | Both patients died 8–9 months after transplant. |
| Provenzale and Graham (1996) | allo-HSCT           | 1                  | Personality changes, seizures, cognitive dysfunction, headache | Diffuse WML multiple foci of hyper-intense signal on T2-weighted images in the brain stem and deep white matter | WNL, EP+L, NG |     | Moderate to severe bilateral slowing | Antemortem histology: vasculitis | F  | Methyl prednisone | Partial response died on day 123 | 71 days |
| Ma et al.       | allo-HSCT               | 1                  | Personality changes, seizures, cognitive dysfunction, headache | Diffuse WML with periventricular predominance | EP + L, NG |     | No brain biopsy | F               | Methyl prednisolone, phenytoin, and sirolimus | Complete response | 14 months after second transplant |
| Shortt et al.   | allo-HSCT               | 1                  | Personality changes, seizures, cognitive dysfunction, headache | Diffuse WML with periventricular predominance | EP + L, NG |     | No brain biopsy | F               | Methyl prednisolone, phenytoin, and sirolimus | Complete response | 14 months after second transplant |
| Kamble et al.   | allo-HSCT/               | 2                  | Right hemiparesis/encephalopathy, seizures            | Infiltrating WML, left frontal parietal lobe with minimal enhancement/patch areas of increased intensity in pontine white matter, caudate nuclei, putamina, bilateral cerebral and cerebellar white matter | WNL/EP+L, NG, normal LDH |     | Perivascular lymphocytic infiltrates composed of T-lymphocytes from the donor predominantly in the brain parenchyma (BB), autopsy: leptomeningeal perivascular inflammation | F (21), G (51) | Diazepam and phenobarbital | 42 (53.2%) died | Conditioning stage (3), day 0–100 (52), day 100–365 (20), 365+ (4) |
| Zhang et al.    | allo-HSCT               | 79                 | Seizures                                              | Demyelination (8), CNS infection (8), intracranial hemorrhage (3), cerebral infarction (2), and CNS tumors (1) | WNL (3), increased pressure or EP (12) |     | Abnormal (2) | CNS fungal infection (BB, 1) | F (21), G (51) | Diazepam and phenobarbital | 42 (53.2%) died | Conditioning stage (3), day 0–100 (52), day 100–365 (20), 365+ (4) |

Abbreviations: F = focal, G = generalized, M = myoclonus, N/A = not available, OLT = orthotopic liver transplant, allo-HSCT = allogeneic hematopoietic stem cell transplant, auto-HSCT = autogenic hematopoietic stem transplant, WML = white matter lesion, CPM = central pontine myelinolysis, EP = elevated protein, EP + L = elevated protein + lymphocytes, NG = normal glucose, LDH = lactate dehydrogenase, Pleo = Pleocytosis, CSF = cerebral spinal fluid, MRI = magnetic resonance imaging, CAT = computer axial tomography, GVHD = graft versus host disease, WNL = within normal limits, BB = brain biopsy.

Literature review describing neurological manifestations in transplant recipients.
Acknowledgments

We would like to acknowledge Dr. Steven J. Schiff for helpful discussions.

References

[1] Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200–6. http://dx.doi.org/10.1182/blood-2004-10-4023.
[2] Aigner B, DW M. Myoclonus: clinical significance and an approach to classification. AMA Arch Neurol 1960;2:600–15.
[3] Guerrini R, Parmegiani L, Kaminska A, Dulac O. Myoclonic astatic epilepsy. Epileptic Syndr Infancy Child Adolesc 2002;3:105–12.
[4] Taylor JW, Schiff D. Neurologic complications. Blood Marrow Transpl. Handb. Springer; 2015. p. 311–21.
[5] Kamble RT, Chang C-C, Sanchez S, Carrum G. Central nervous system graft-versus-host disease: report of two cases and literature review. vol. 39. 2007. http://dx.doi.org/10.1038/sj.bmt.1705540.
[6] Provenzale JM, Graham MC. Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. Am J Neuroradiol 1996;17:1290–4.
[7] Marosi C, Budka H, Grimm G, Zeitlinger J, Sluga E, Brunner C, et al. Fatal encephalitis in a patient with chronic graft-versus-host disease, vol. 6. ; 1990.
[8] Iwasaki Y, Sako K, Ohara Y, Miyazawa M, Minegishi M, Tsuchiya S, et al. Subacute panencephalitis associated with chronic graft-versus-host disease. Acta Neuropathol 1993;85(5):566–72.
[9] Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol 1991; 7:457–63. http://dx.doi.org/10.1016/0887-8994(91)90031-F.
[10] Staral TJ, Schleeh SA, Mazzeoie M, Abrele JA, Portier KA, Schlieter GP, et al. Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus. Ann Surg 1978;187:236–40. http://dx.doi.org/10.1097/00000658-197803000-00003.
[11] Adams HP, Conomon B, Hoenigsberger L, Buckels J, Ponsford S, Boon A, et al. Neurological complications following liver transplantation. Lancet 1987;329:949–51. http://dx.doi.org/10.1016/S0140-6736(87)90294-7.
[12] Ma M, Barnes G, Pulliam J, Jetter D, Baumann RJ, Berger JR. CNS angiitis in graft vs host disease. Neurology 2002;59:1994–7.
[13] Shortt J, Hutton E, Faragher M, Spencer A. Central nervous system graft-versus-host disease post allogeneic stem cell transplant. Br J Haematol 2006;132:245–7. http://dx.doi.org/10.1111/j.1365-2141.2005.05864.x.
[14] Zhang XY, Huang XJ, Liu KY, Xu LF, Liu HJ, Chen H, et al. Idiopathic inflammatory demyelinating diseases of the central nervous system in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors and survival. Chin Med J (Engl) 2013;126:1096–102. http://dx.doi.org/10.1111/ctr.12000.